Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: A multicentre retrospective study

Daniela Melis, G. Parenti, R. Gatti, R. Della Casa, R. Parini, E. Riva, A. B. Burlina, C. Dionisi Vici, M. Di Rocco, F. Furlan, M. Torcoletti, F. Papadia, A. Donati, V. Benigno, G. Andria

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The efficacy of ACE-inhibitors in decreasing microalbuminuria and proteinuria has been reported in a few patients with glycogen storage disease type 1 (GSD1); however, no case-control study has ever been published. Aim: The aim of the current study was to evaluate the efficacy of ACE-inhibitors in reducing glomerular hyperfiltration, microalbuminuria and proteinuria, and in delaying the progression of renal damage. Patients and methods: Ninety-five patients (median age at the time of the study: 14.5 years) were enrolled from nine Italian referral centres for metabolic diseases. A retrospective study of a 10-year follow-up was conducted in order to compare the evolution of these parameters in treated patients with those who were not treated with ACE-inhibitors. Results: A significant and progressive decrease of glomerular filtration rate was observed in treated patients vs. those who were not treated with ACE-inhibitors (P <0.05). No difference was observed for microalbuminuria and proteinuria between the two groups of patients. Moreover, the ACE-inhibitors significantly delayed the progression from glomerular hyperfiltration to microalbuminuria, but not that from microalbuminuria to proteinuria. Conclusions: The results of the present study underline the importance of a strict follow-up of renal function in GSD1 patients. The detection of glomerular hyperfiltration suggests precocious initiation of ACE-inhibitor treatment to delay the progression of renal damage. A randomized prospective study is needed to establish for certain the real effectiveness of this treatment in GSD1 patients.

Original languageEnglish
Pages (from-to)19-25
Number of pages7
JournalClinical Endocrinology
Volume63
Issue number1
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Glycogen Storage Disease Type I
Angiotensin-Converting Enzyme Inhibitors
Multicenter Studies
Retrospective Studies
Kidney
Proteinuria
Therapeutics
Time and Motion Studies
Metabolic Diseases
Glomerular Filtration Rate
Case-Control Studies
Referral and Consultation
Prospective Studies

ASJC Scopus subject areas

  • Endocrinology

Cite this

Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1 : A multicentre retrospective study. / Melis, Daniela; Parenti, G.; Gatti, R.; Della Casa, R.; Parini, R.; Riva, E.; Burlina, A. B.; Vici, C. Dionisi; Di Rocco, M.; Furlan, F.; Torcoletti, M.; Papadia, F.; Donati, A.; Benigno, V.; Andria, G.

In: Clinical Endocrinology, Vol. 63, No. 1, 07.2005, p. 19-25.

Research output: Contribution to journalArticle

Melis, D, Parenti, G, Gatti, R, Della Casa, R, Parini, R, Riva, E, Burlina, AB, Vici, CD, Di Rocco, M, Furlan, F, Torcoletti, M, Papadia, F, Donati, A, Benigno, V & Andria, G 2005, 'Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: A multicentre retrospective study', Clinical Endocrinology, vol. 63, no. 1, pp. 19-25. https://doi.org/10.1111/j.1365-2265.2005.02292.x
Melis, Daniela ; Parenti, G. ; Gatti, R. ; Della Casa, R. ; Parini, R. ; Riva, E. ; Burlina, A. B. ; Vici, C. Dionisi ; Di Rocco, M. ; Furlan, F. ; Torcoletti, M. ; Papadia, F. ; Donati, A. ; Benigno, V. ; Andria, G. / Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1 : A multicentre retrospective study. In: Clinical Endocrinology. 2005 ; Vol. 63, No. 1. pp. 19-25.
@article{1404fa7e682a4249a6aba4afdf31e41a,
title = "Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: A multicentre retrospective study",
abstract = "Background: The efficacy of ACE-inhibitors in decreasing microalbuminuria and proteinuria has been reported in a few patients with glycogen storage disease type 1 (GSD1); however, no case-control study has ever been published. Aim: The aim of the current study was to evaluate the efficacy of ACE-inhibitors in reducing glomerular hyperfiltration, microalbuminuria and proteinuria, and in delaying the progression of renal damage. Patients and methods: Ninety-five patients (median age at the time of the study: 14.5 years) were enrolled from nine Italian referral centres for metabolic diseases. A retrospective study of a 10-year follow-up was conducted in order to compare the evolution of these parameters in treated patients with those who were not treated with ACE-inhibitors. Results: A significant and progressive decrease of glomerular filtration rate was observed in treated patients vs. those who were not treated with ACE-inhibitors (P <0.05). No difference was observed for microalbuminuria and proteinuria between the two groups of patients. Moreover, the ACE-inhibitors significantly delayed the progression from glomerular hyperfiltration to microalbuminuria, but not that from microalbuminuria to proteinuria. Conclusions: The results of the present study underline the importance of a strict follow-up of renal function in GSD1 patients. The detection of glomerular hyperfiltration suggests precocious initiation of ACE-inhibitor treatment to delay the progression of renal damage. A randomized prospective study is needed to establish for certain the real effectiveness of this treatment in GSD1 patients.",
author = "Daniela Melis and G. Parenti and R. Gatti and {Della Casa}, R. and R. Parini and E. Riva and Burlina, {A. B.} and Vici, {C. Dionisi} and {Di Rocco}, M. and F. Furlan and M. Torcoletti and F. Papadia and A. Donati and V. Benigno and G. Andria",
year = "2005",
month = "7",
doi = "10.1111/j.1365-2265.2005.02292.x",
language = "English",
volume = "63",
pages = "19--25",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1

T2 - A multicentre retrospective study

AU - Melis, Daniela

AU - Parenti, G.

AU - Gatti, R.

AU - Della Casa, R.

AU - Parini, R.

AU - Riva, E.

AU - Burlina, A. B.

AU - Vici, C. Dionisi

AU - Di Rocco, M.

AU - Furlan, F.

AU - Torcoletti, M.

AU - Papadia, F.

AU - Donati, A.

AU - Benigno, V.

AU - Andria, G.

PY - 2005/7

Y1 - 2005/7

N2 - Background: The efficacy of ACE-inhibitors in decreasing microalbuminuria and proteinuria has been reported in a few patients with glycogen storage disease type 1 (GSD1); however, no case-control study has ever been published. Aim: The aim of the current study was to evaluate the efficacy of ACE-inhibitors in reducing glomerular hyperfiltration, microalbuminuria and proteinuria, and in delaying the progression of renal damage. Patients and methods: Ninety-five patients (median age at the time of the study: 14.5 years) were enrolled from nine Italian referral centres for metabolic diseases. A retrospective study of a 10-year follow-up was conducted in order to compare the evolution of these parameters in treated patients with those who were not treated with ACE-inhibitors. Results: A significant and progressive decrease of glomerular filtration rate was observed in treated patients vs. those who were not treated with ACE-inhibitors (P <0.05). No difference was observed for microalbuminuria and proteinuria between the two groups of patients. Moreover, the ACE-inhibitors significantly delayed the progression from glomerular hyperfiltration to microalbuminuria, but not that from microalbuminuria to proteinuria. Conclusions: The results of the present study underline the importance of a strict follow-up of renal function in GSD1 patients. The detection of glomerular hyperfiltration suggests precocious initiation of ACE-inhibitor treatment to delay the progression of renal damage. A randomized prospective study is needed to establish for certain the real effectiveness of this treatment in GSD1 patients.

AB - Background: The efficacy of ACE-inhibitors in decreasing microalbuminuria and proteinuria has been reported in a few patients with glycogen storage disease type 1 (GSD1); however, no case-control study has ever been published. Aim: The aim of the current study was to evaluate the efficacy of ACE-inhibitors in reducing glomerular hyperfiltration, microalbuminuria and proteinuria, and in delaying the progression of renal damage. Patients and methods: Ninety-five patients (median age at the time of the study: 14.5 years) were enrolled from nine Italian referral centres for metabolic diseases. A retrospective study of a 10-year follow-up was conducted in order to compare the evolution of these parameters in treated patients with those who were not treated with ACE-inhibitors. Results: A significant and progressive decrease of glomerular filtration rate was observed in treated patients vs. those who were not treated with ACE-inhibitors (P <0.05). No difference was observed for microalbuminuria and proteinuria between the two groups of patients. Moreover, the ACE-inhibitors significantly delayed the progression from glomerular hyperfiltration to microalbuminuria, but not that from microalbuminuria to proteinuria. Conclusions: The results of the present study underline the importance of a strict follow-up of renal function in GSD1 patients. The detection of glomerular hyperfiltration suggests precocious initiation of ACE-inhibitor treatment to delay the progression of renal damage. A randomized prospective study is needed to establish for certain the real effectiveness of this treatment in GSD1 patients.

UR - http://www.scopus.com/inward/record.url?scp=22044453413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044453413&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2005.02292.x

DO - 10.1111/j.1365-2265.2005.02292.x

M3 - Article

C2 - 15963056

AN - SCOPUS:22044453413

VL - 63

SP - 19

EP - 25

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 1

ER -